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Abstract
Extracellular signal-regulated kinase (ERK) signalling plays a central role in various biological processes, including cell
migration, but it remains unknown what factors directly regulate the strength and duration of ERK activation. We found
that, among the B56 family of protein phosphatase 2A (PP2A) regulatory subunits, B56c1 suppressed EGF-induced cell
migration on collagen, bound to phosphorylated-ERK, and dephosphorylated ERK, whereas B56a1 and B56b1 did not.
B56c1 was immunolocalized in nuclei. The IER3 protein was immediately highly expressed in response to costimulation of
cells with EGF and collagen. Knockdown of IER3 inhibited cell migration and enhanced dephosphorylation of ERK. Analysis
of the time course of PP2A-B56c1 activity following the costimulation showed an immediate loss of phosphatase activity,
followed by a rapid increase in activity, and this activity then remained at a stable level that was lower than the original
level. Our results indicate that the strength and duration of the nuclear ERK activation signal that is initially induced by ERK
kinase (MEK) are determined at least in part by modulation of the phosphatase activity of PP2A-B56c1 through two
independent pathways.
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Introduction
Extracellular signal-regulated kinase (ERK) signalling plays a
central role in basic biological processes of cells. A growth factor
initiates a cell signal by binding to its cell surface receptor, and this
is followed by activation of ERK via phosphorylation by ERK
kinase (MEK) at threonine and tyrosine residues in the TEY motif
(pTpYERK) [1–3]. Subsequently, ERK phosphorylates about 200
distinct substrates, ranging from transcription factors to cytoskel-
etal proteins, and from protein kinases to phosphatases [4]. The
great diversity of ERK substrates is consistent with the diverse
effects of ERK on cellular functions [5,6]. The question of how a
single event is chosen among the variety of ERK-induced
functions has been extensively studied, and it appears that
particular cellular responses require a specific strength and
duration of ERK activation [7,8]. Initially, it was thought that
sustained ERK activation caused cell differentiation, while
transient ERK activation led not to proliferation, but to migration
[9,10]. However, cell proliferation also requires sustained ERK
activation associated with integrin-mediated anchorage [11],
which induces a gradual increase in ERK activation that is
subsequently sustained [12]. A growth factor initially activates
ERK rapidly and transiently [13], and then synergistic signalling
from the anchorage and the growth factor induces robust and
sustained ERK activation [11,14]. Thus, all anchorage-dependent
cellular events, including migration [15–18], proliferation [11,19],
differentiation [9] and survival [20], induced by a growth factor
require sustained activation of ERK [21].
The choice of cellular outcome is presumably influenced by
differences of stimulus intensity and duration or growth factor
concentration. It has been shown that low concentrations of a
growth factor induce cell proliferation but not cell migration,
whereas higher concentrations induce cell migration on a matrix
and inhibit cell proliferation [16,22]. Thus, subtle differences of
growth factor stimulation produce differences in the strength and
duration of ERK signalling, leading to specific biological outcomes
through distinct mechanisms involving efficient ERK sensors,
including phosphorylation of c-FOS protein [23]. The strength of
ERK activation is mainly determined by the balance of activities of
MEK and constitutively active phosphatases. It is also modulated
by inactivating signals, which could originate from cross-talk with
a parallel signal, a negative feedback signal or a positive feedback
signal. Thus, the strength and duration of ERK activation appear
to be precisely regulated by a complex network of factors, many of
which remain to be fully defined.
It seems likely that phosphatases are important modulators of
ERK activation. One or two phosphorylated sites in dual-
phosphorylated ERK could be dephosphorylated and inactivated
by dual-specific mitogen-activated protein kinase (MAPK) phos-
phatases (MKPs) [24], tyrosine phosphatases in specialized cells
[1,2], and Ser/Thr protein phosphatases [1,25,26]. MKPs are
well-known phosphatases that specifically dephosphorylate
pTpYERK through a posttranscriptional negative feedback
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mechanism [24,27], which would be involved in halting ERK-
induced cellular events. A protein-tyrosine phosphatase (PTP) acts
as an important regulator of ERK in hematopoietic cells [28],
although PTPs are dispensable for ERK regulation in other cells
[29]. On the other hand, accumulating evidence indicates that
PP2A has complex inhibitory and stimulatory effects on growth
factor- and/or adhesion-induced signalling, in particular the ERK
cascade. PP2A substrates include receptor tyrosine kinases [30,31],
receptor-associated adaptor proteins [32], and all three kinases of
the ERK cascade, Raf1 [33–35], MEK [36,37], and ERK
[25,38,39]. PP2A influences tumor progression [40–42]. It is also
well-known to be involved in one of the most important
anchorage-dependent cellular events, i.e., cell motility [43,44],
which is in turn involved in cancer invasion and metastasis.
The great diversity of PP2A functions has been ascribed to the
diversity of its B regulatory subunits [42]. The B regulatory
subunits of PP2A heterotrimer are divided to B, B56 (B9) and B99
families. Each family consists of several gene products and splicing
variants, and their individual functions and substrate specificities
have been partly identified. Ba- and Bd-containing PP2A promote
activation of ERK by dephosphorylating the Raf1 inhibitory
phosphorylation site [35]. It has also been found that PP2A with
members of the B56 family can dephosphorylate ERK directly,
and that this action is related to cell migration. Letourneux et al.
[39] and Rocher et al. [45] reported that PP2A-B56b1, B56b2,
B56c1 and B56c2 dephosphorylate ERK directly, but they did not
identify a corresponding cellular event. However, it was also
reported that B56c1 inhibited locomotion through dephosphory-
lation of paxillin or mdm2 [46,47]. p53 protein was also reported
to be a substrate of PP2A-B56c1 and -B56c3 [48,49]. PP2A-
B56b1 dephosphorylates Pim-1 [50], TrkA [31], tyrosine hydrox-
ylase [51], Akt1 [52,53] and Emi2 [54]. In addition, B56a targets
cMyc, APC, ankyrin B [55] and SK1 [56], and PP2A-B56c3
dephosphorylates ChK2 [57]. Thus, the functions of the B56
family members appear to be quite redundant, and it seems likely
that the central regulatory mechanism of ERK activation remains
to be fully defined.
In this work, we aimed to investigate which subunits of the B56
family are directly involved in ERK activation leading to cell
migration. To address this question, we carried out costimulation
experiments with EGF and collagen, using Calu1 lung carcinoma
cells and mouse Swiss 3T3 fibroblasts. We found that ERK in
nuclei is dephosphorylated only by PP2A-B56c1. Furthermore, we
found two temporally distinct kinetic curves involving PP2A-
B56c1; initial loss of activity following stimulation, then sustained
low-level activation caused by prompt synthesis of IER3. Our
results indicate that the fidelity of the strength and duration of the
nuclear ERK activation associated with cell migration is main-
tained by dynamic regulation mediated by PP2A-B56c1.
Materials and Methods
Cells
Calu1 lung squamous cell carcinoma line [58] was kindly
provided by Dr Takashi Takahashi (Aichi Cancer Institute, Japan),
but is also available through American Type Culture Collection.
OSC19 oral squamous cell carcinoma line [59] was kindly
provided by Dr Yokoi (Sapporo Medical University, Japan).
Mouse Swiss 3T3 fibroblasts [59] and a variety of human
squamous cell carcinoma lines including HSC3 oral cell carcino-
ma [60], EBC1 lung carcinoma, LK2 lung carcinoma and A431
esophageal carcinoma [16] were obtained from Japanese Collec-
tion of Research Bioresources (Osaka, Japan). The cells of
subconfluent cultures, maintained in MEM containing 10% fetal
bovine serum, were harvested with trypsin, and then the trypsin
was inactivated with soybean trypsin inhibitor (Sigma, St Louis,
MO, USA). The cells were washed with serum-free MEM
containing 0.5% heat-denatured bovine serum albumin (Sigma)
and were used for experiments.
Migration Assay
Cell migration assay was performed in 24-well Transwell
chambers containing a polycarbonate membrane with a pore size
of 8 mm (Corning, Acton, MA, USA) [61]. The undersurface of
the membrane was coated with 10 mg/ml type I collagen solution
in PBS. Aliquots of 50,000 cells were treated with or without EGF.
Cells were treated with PD98059 or cycloheximide for 30 min
prior to EGF stimulation, when necessary. The cells were loaded
onto membranes in quadruplicate, and incubated in a CO2
incubator at 37uC. The cells that migrated on the collagen-coated
surface were stained with 2% crystal violet. The membranes were
washed with water, the dye was eluted with 10% acetic acid, and
the optical density of the eluate at 620 nm was measured. When
the number of migrated cells was too small for colorimetric assay,
the cells were counted directly under a microscope.
Plasmids
pCEP plasmids containing B56a1, B56b1 or B56c1 cDNA with
a 4HA tag (pCEP4HAB56a1, pCEP4HAB56b1, pCE-
P4HAB56c1) were provided by Dr David Virshup [62]. Mouse
B56c1 containing vector (pCX4bsr-B56c1) was provided by Dr Ito
[63].
DNA Transfection
The vectors containing B56 were transfected into cells using
Lipofectamine 2000 (Invitrogen). pCEP4HAB56a1, pCE-
P4HAB56b1 and pCEP4HAB56c1 plasmids were used to
transfect Calu1 cells and pCX4bsr-B56c1 to transfect mouse
Swiss 3T3 cells. The transfected cells were selected with
hygromycin or blasticidin for 1 month and stable cell lines were
established. The pCEP4HAB56b1 and pCEP4HAB56c1 plasmids
were also used to transiently transfect Calu1 cells in conjunction
with Lipofectamine 2000, and the transfected cells were used for
experiments 24 hour later.
RNAi
To knock down a gene, double-stranded short interference
RNA (d-siRNA) was generated using a Block-iT RNAi TOPO
Transcription Kit and a Block-iT Dicer RNAi Kit (Invitrogen). A
sequence covering IER3 cDNA (470 bp) was amplified by RT-
PCR using a set of primers. The resultant PCR product was joined
to a linker containing a T7 RNA polymerase-recognizing
sequence. From the linked sequence a sense template and an
antisense template were amplified with the same set of primers and
T7 polymerase specific primer. Each DNA template was
converted to single-stranded RNA using T7 RNA polymerase.
Sense RNA and antisense RNA were annealed to generate double-
stranded RNA. The double-stranded RNA was treated with dicer.
The resultant 20–23 bp d-siRNA was transfected into Calu1 cells
with Lipofectamine 2000. Gene-specific mRNA expression was
measured by a real-time PCR system (ABI PRISM 7000 or Viia7,
Applied Biosystems, Foster City, CA, USA), and the specificity and
efficiency of knockdown were calculated. For mock RNAi an
intron sequence of b5 integrin gene [64], which is unrelated to the
genes examined in the present study, was used.
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Western Blotting
Cells were lysed with SDS sample buffer (625 mM Tris-HCl
buffer, pH 6.8, 2% SDS, 10% glycerol, 01% bromophenol blue)
with or without 6% mercaptoethanol. Samples were subjected to
10–13% SDS-PAGE. The samples run in the gel were transferred
onto polyvinylidene fluoride membranes (Amersham Hybond-P,
GE Healthcare, Buckinghamshire, UK), and reacted with anti-
phospho-ERK1/2 (Thr202/Tyr204) antibodies (Cell Signaling
Technology, Danvers, MA), anti-phospho-ERK1/2 (Tyr204) anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-
PP2A-Ca/bantibodies (Santa Cruz Biotechnology), anti-actin
antibodies (Sigma), anti-phospho-MEK (Ser218/Ser222), anti-
IER3 antibodies (Abnova, Walnut, CA, USA), or anti-HA
antibodies (Roche, Manheim, Germany). Then, peroxidase-
labeled anti-rabbit IgG antibodies (Cell Signaling Technology),
peroxidase-labeled anti-rat antibodies (Cell Signaling Technology)
or peroxidase-labeled anti-goat IgG antibodies (Santa Cruz
Biotechnology) were applied. Visualisation was performed using
a chemiluminescence system (ECL Western Blotting Detection
Reagents, Amersham Biosciences, Buckinghamshire, UK). To
compare protein levels, the lysates were run in a single
polyacrylamide gel and band densities were determined by
densitometric analysis.
Dot Blotting
Quantification of IER3 protein was examined by dot blot
analysis. Cells were lysed with SDS sample buffer or lysis buffer.
Samples of equal volume were applied in triplicate, dried and
crosslinked to PVDF membrane by an ultraviolet crosslinker (UV
stratalinker 1800, Stratagene, La Jolla, CA, USA). The membrane
was reacted with anti-IER3 antibodies and peroxidase-labelled
anti-rabbit IgG antibodies. Chemiluminescence reaction was
performed using ECL Western Blotting Detection Reagent and
evaluated with an image analyzer (Lumi-Imager F1, Roche
Diagnostics). Protein concentrations in the samples were measured
using RC-DC Protein Assay. A sample with maximum protein
concentration was serially diluted to prepare a standard curve so
that relative amounts could be obtained. The amounts of IER3
Figure 1. EGF- and collagen-stimulated cell migration and ERK phosphorylation. (A, C–F) Migration assay on collagen using Calu1
carcinoma cells (A, C, E) or Swiss 3T3 fibroblasts (D, F). The cells were allowed to migrate for 5 hours (C, E) or overnight (A, D, F). (A) The dose-
dependent effect of EGF on Calu1 cell migration. (B) The dose-dependent effect of EGF on threonine- and tyrosine-phosphorylation of ERK1/2
(pTpYERK) in Calu1 cells. The densities of the bands were measured and plotted on the line chart. (C, D) The effect of PD98059 on EGF-induced cell
migration. (E, F) The effect of cycloheximide (CHX) on EGF-induced migration. (G) Kinetics of pTpYERK. Calu1 cells were treated with 10 ng/ml EGF,
and the cells were kept in suspension (EGF) or loaded on collagen-coated plates (EGF+COL). The densities of the bands were measured and plotted
on the line charts. The levels at 0 min and 15 min were determined by densitometric analysis of samples run in the same gel. One way analysis of
variance (A, C, D, E, F) or Student’s t-test (G) was used for statistical analysis.
doi:10.1371/journal.pone.0063729.g001
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determined from the standard curve were calibrated with the
protein concentrations of the samples.
Pulldown Assay
HA-B56 transfected Calu1 cells were dissolved in lysis buffer
(50 mM Tris-HCl buffer, pH 7.4/150 mM NaCl/1% NP-40/
Figure 2. B56c1 overexpression inhibits both cell migration and ERK phosphorylation. (A) The effect of B56c1 overexpression on
migration of 3T3 cells. (B) The effect of B56c1 overexpression on ERK phosphorylation in 3T3 cells. Bars, 10 mm. (C) The effects of B56 overexpression
on migration using permanently transfected Calu1 cells. Migration of Calu1 cells, which were permanently transfected with pCEPB56a1, pCEPB56b1
or pCEPB56c1, was compared with that of untransfected Calu1 cells (null). B56 protein in each cell line (26106 cells) is shown by western blotting with
anti-HA antibodies following to immunoprecipitation with anti-HA antibodies, and coprecipitated C subunit is shown by western blotting with anti-
PP2A-C subunit antibodies. To detect binding of C subunit to B56b1 protein in B56b1-transfected Calu1 cells, 66106 cells were used and the blot is
shown in the right. (D) The effects of B56 overexpression on migration using transiently transfected Calu1 cells. Migration of Calu1 cells, which were
transiently transfected with pCEPB56c1, was compared with that of Calu1 cells, which were transiently transfected with empty plasmids. (E) The effect
of B56c1 overexpression on kinetics of pTpYERK and pYERK after costimulation in Calu1 cells. Scheffe’s multiple comparison after one way analysis of
variance (C) or two way analysis of variance (D) was used for statistical analysis.
doi:10.1371/journal.pone.0063729.g002
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0.25% sodium deoxycholate/1 mM phenylmethylsulfonyl fluo-
ride/1 mg/ml leupeptin/2 mg/ml aprotinin/10 mM mercaptoeth-
anol). Proteins in the cell lysates were immunoprecipitated with
protein G Sepharose (Amersham Biosciences) and specific
antibodies. The precipitate was washed and SDS-sample buffer
with or without mercaptoethanol was added. Protein of interest in
the immune complex was detected by western blotting. As a
negative control, Protein G Sepharose was suspended in cell lysate
without the specific antibodies.
In vitro Immune Complex Phosphatase Assay
To quantify PP2A-B56c1 phosphatase activity, a fluorometric
phosphatase assay [65] was used. Calu1-B56c1 cells, which were
stimulated with EGF and loaded onto a collagen-coated plate for a
suitable period, were lysed with lysis buffer. The protein
concentration in the supernatant was measured, and samples
containing equal amounts of protein were used. B56c1 was
immunoprecipitated from the lysate with anti-HA antibodies and
protein G Sepharose. The immobilized B56c1 complex was
reacted with 4-methylumbelliferyl phosphate (Wako Pure Chem-
ical Industries, Osaka, Japan) in phosphatase buffer (50 mM Tris-
HCl, pH 7.5/1 mM MgCl2/1 mM EGTA), and the fluorescence
intensity of the released 4-methylumbelliferone was measured with
an emission wavelength of 450 nm and excitation wavelength of
360 nm using a microplate fluorometer (FluoDia T70, Photon
Technology International, Birmingham, NJ, USA).
To qualify phosphatase activity of PP2A-B56 on pTpYERK,
B56a1, B56b1 and B56c1 were immunoprecipitated with anti-HA
antibodies, and then immobilized on Protein G Sepharose. Crude
cell lysate containing pTpYERK after stimulation with EGF was
Figure 3. Nuclear localization of pTpYERK and B56c1. (A) Immunolocalization of B56c1 in 3T3-B56c1 cells and pTpYERK in 3T3 cells stimulated
with EGF on collagen was analyzed using a confocal laser scanning microscope. To detect mouse B56c1 protein anti-mouse B56c1 antibodies were
used. (B) Immunolocalization of pTpYERK, B56a1, B56b1 and B56c1 in Calu1 or B56-transfected Calu1 cells stimulated with EGF on collagen. HA-
tagged B56 proteins were detected using anti-HA antibodies. Nuclear or perinuclear immunolocalization was detected by a confocal laser scanning
microscope. (C) The time course of B56c1 in nuclei of B56c1-transfected Calu1 cells on collagen after stimulation with EGF using a conventional
fluorescence photomicroscope. Nuclei were stained with Hoechst 33258. Bars, 10 mm. (D) B56c1 protein in nuclei. EGF was added to suspension of
B56c1-transfected Calu1 cells, and the cells were immediately loaded on a collagen-coated plastic plate. Extracted nuclear protein from the cells with
no treatment (NT) and both with EGF and collagen (EGF+COL) was used for western blot analysis using anti-HA antibodies. Paired t-test was used for
statistical analysis.
doi:10.1371/journal.pone.0063729.g003
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used as a substrate. Immobilized B56 immune complexes were
suspended in the crude cell lysate. As a negative control, Protein G
Sepharose without immune complex was reacted with the crude
cell lysate.
Protein Assay
Since cells placed on a collagen-coated plate for less than 5 min
were hard to fully collect, protein concentrations were measured
using a protein assay kit (RC-DC Protein Assay, Bio-Rad,
Hercules, CA, USA) and samples with equal protein amounts
were used for western blotting, dot blotting and phosphatase assay.
Extraction of Nuclear Protein
Cytoplasmic extraction buffer (120 mM KCl/20 mM Tris-HCl
buffer, pH 7.9/2 mM EDTA/2 mM dithiothreitol/1 mM phe-
nylmethylsulfonyl fluoride/1 mg/ml leupeptin/2 mg/ml aprotinin)
with NP-40 was added to cells. Preipitated nuclei after centrifu-
gation were washed with cytoplasmic extraction buffer. Then,
nuclear extraction buffer (40 mM Tris-HCl buffer, pH 7.9/
800 mM NaCl, 30 mM EDTA/50% glycerol) was added,
vortexed and centrifuged. The resultant supernatant was used
for analysis of nuclear protein.
Immunofluorescence
Glass slides with 8 plastic chambers (Lab-Tek II Chamber
Slides, Nunc, Rochester, NY) were coated with 10 mg/ml type I
collagen solution. Aliquots of 5,000 cells were loaded into each
well and the slide was placed in a CO2 incubator for 30 min, and
then the cells were stimulated with EGF or not stimulated. The
cells were fixed with 3% paraformaldehyde, permeabilized with
0.01% Triton X-100, blocked with 2% BSA, and then incubated
with anti-HA antibodies, anti-phospho-ERK1/2 (Thr202Tyr204)
antibodies, anti-mouse B56FFF1 antibodies (provided by Dr
Nojima), or anti-actin antibodies. As secondary antibodies, Alexa
Fluor 488-labeled anti-rabbit antibodies, Alexa Fluor 488-labeled
anti-rat IgG antibodies, or Alexa Fluor 594-labeled anti-rabbit
antibodies (Molecular Probes, Eugene, OR) were used. Immuno-
fluorescence was observed under a conventional fluorescence
microscope (BX50, Olympus, Tokyo, Japan) or a confocal laser
scanning microscope (LSM510, Carl Zeiss, Munich, Germany).
Nucei were counterstained with Hoechst33258 (Dojindo, Kuma-
moto, Japan).
Statistics
Student’s t-test was used for comparison of the averages
between two groups. For multiple comparisons, one- or two-way
analysis of variance was used and for the subsequent comparison
between two groups among them, Scheffe’s multiple comparison
was used.
Results
Cell Migration Requires Intense and Sustained Activation
of ERK
Migratory activities of various cultured cell lines on collagen
were examined using a 5-hour or overnight migration assay. Both
Calu1 cells of human lung carcinoma origin and Swiss 3T3 cells of
mouse fetal fibroblast origin migrated in response to EGF in this
assay system (Figure 1A, F). We further examined a variety of
squamous carcinoma cells, including A431 esophageal carcinoma,
EBC1 lung carcinoma, LK2 lung carcinoma, OSC19 oral
carcinoma and HSC3 oral carcinoma cells, and found that all of
them migrated similarly in response to EGF in this assay. The level
of pTpYERK in a suspension of Calu1 cells, as estimated by
western blotting, was also increased dose-dependently by EGF
(Figure 1B). The minimal concentration of EGF that induced both
the maximum cell migration and the highest phosphorylation of
ERK was 10 ng/ml (Figure 1A, B). Therefore, 10 ng/ml EGF was
used for all subsequent experiments in the present study.
The EGF-induced migration of Calu1 cells and 3T3 cells was
inhibited by the MEK inhibitor PD98059 (Figure 1C, D),
indicating that the EGF-induced migration on collagen is
mediated by ERK. The protein synthesis inhibitor cycloheximide
also inhibited the EGF-induced migration of Calu1 cells
(Figure 1E) and 3T3 cells (Figure 1F) in a dose-dependent
Figure 4. PP2A-B56c1 binds to and dephosphorylates
pTpYERK. (A) Pull down assay. HA-tagged B56 protein in B56-
transfected Calu1 cells was immunoprecipitated with anti-HA antibod-
ies. pTpYERK, IER3 and B56s in the immune complex were detected by
western blotting. Similarly, the complex immunoprecipitated from 3T3-
B56c1 cells with rabbit anti-pTpYERK antibodies was run in polyacryl-
amide gel under non-reducing conditions and B56c1 was detected by
western blotting using rabbit anti-mouse B56c1 antibodies and HRP-
labeled anti-rabbit IgG antibodies. (B) Immune complex phosphatase
assay. Immobilized PP2A trimer co-immunoprecipitated with anti-HA
antibodies on protein G-Sepharose beads was used as an enzyme and
pTpYERK-rich cell lysate of Calu1 cells stimulated with EGF was used as
a substrate. Beads suspensions were incubated for 30 min in the crude
substrate solution. pTpYERK in the reacted lysate was detected by
western blotting. Immunoprecipitated enzyme was quantitated by
western blotting using rat anti-HA antibodies.
doi:10.1371/journal.pone.0063729.g004
Figure 5. IER3 protein is promptly synthesized in response to
EGF and adhesion. (A) Kinetics of IER3 protein expression evaluated
by western blotting. (B) Kinetics of IER3 protein expression measured by
dot blot analysis. (C) The effect of cycloheximide on early migration of
Calu1 cells. Two way analysis of variance was used for statistical
analysis.
doi:10.1371/journal.pone.0063729.g005
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manner, indicating that this migration requires de novo protein
synthesis.
When EGF was added to a suspension of Calu1 cells (EGF-only
group), the level of pTpYERK was increased, reaching the
maximum 15 min later, and then the ERK phosphorylation level
continuously decreased until 60 min (Figure 1G). When the cells
were stimulated with EGF and then immediately loaded onto
collagen-coated dishes (EGF+COL), the level of pTpYERK was
also increased at 15 min, but this level of phosphorylation then
persisted until 60 minutes (Figure 1G). The levels of pTpYERK
phosphorylation at 0 min and 15 min under these two different
conditions were determined by densitometric analysis of samples
run in the same gel. This analysis showed that the level of
pTpYERK at 15 min under the EGF+COL condition was
significantly higher than that under the EGF-only condition.
Thus, both intense and sustained activation of ERK induced by
EGF+COL stimulation are required for cell migration.
Overexpression of B56c1 Reduces Both EGF-induced Cell
Migration and Phosphorylation of ERK
To determine what factors, other than MEK, might induce or
maintain the intense and sustained activation of ERK following
EGF treatment, we analysed the potential involvement of the B56
family of PP2A heterotrimers. The mouse B56c1 cDNA-contain-
ing plasmid pCX4bsr was transfected into 3T3 cells (3T3-B56c1).
The resulting overexpression of B56c1 led to inhibition of EGF-
induced migration of the cells (Figure 2A). The effect of B56c1
overexpression on ERK phosphorylation was also examined using
immunofluorescence assay. 3T3-B56c1 cells and 3T3 cells were
stimulated with EGF and immediately loaded onto collagen-
coated glass slides, and then ERK phosphorylation was analysed.
The immunofluorescence signal of pTpYERK in 3T3-B56c1 cells
after EGF stimulation was weaker than that in 3T3 cells
(Figure 2B).
pCEP plasmids containing B56a1, B56b1 or B56c1 were
permanently transfected into Calu1 cells (pCalu1-B56a1, pCalu1-
B56b1, pCalu1-B56c1). Since all carcinoma cell lines we
examined migrated well even when EGF was not added, we
examined the effect of B56c1 overexpression on migration of
Calu1 cells in the presence and absence of EGF. pCalu1-B56c1
cells showed significantly less migration on collagen than did
Calu1 cells, both when the cells were stimulated with EGF and
when they were not EGF-stimulated (Figure 2C). The pCalu1-
B56a1 cells and pCalu1-B56b1 cells migrated similarly to Calu1
cells with or without EGF (Figure 2C). To know if the
overexpressed B56 protein forms a complex with C catalytic
subunit, pulldown assay was performed. Coprecipitation of C
subunit with B56a1 and B56c1 was detected, and that with B56b1
was not detected when cells with the same count were used
(Figure 2C). Coprecipitation of C subunit with B56b1 was
detected after the similar protein level of B56b1 to those of
B56a1 and B56c1 was used (Figure 2C).
We also examined the migratory activities of Calu1 cells
transiently transfected with pCEP plasmids containing B56c1
Figure 6. IER3 knockdown decreases cell migration and increase ERK dephosphorylation. (A) The effect of IER3 RNAi on migration of
Calu1 cells. (B) The effect of RNAi on IER3 mRNA expression. (C) The effect of IER3 RNAi on the structure of actin cytoskeleton. The numbers of cells
with cytoplasmic processes were counted under a fluorescence microscope. (D) The effect of IER3 RNAi on kinetics of pYERK and pTpYERK. Bars,
10 mm. Two way analysis of variance (A) or Student’s t-test (B, C, D) was used for statistical analysis.
doi:10.1371/journal.pone.0063729.g006
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(tCalu-mock). The migratory activity of the transfected cells was
compared to that of Calu1 cells that had been transiently
transfected with empty pCEP plasmids (tCalu1-mock). The assay
showed that the migration of tCalu1-B56c1 cells was significantly
lower than that of tCalu1-mock cells (Figure 2D).
Western blotting indicated that the level of pTpYERK in 3T3-
B56c1 cells after EGF+COL stimulation was slightly lower than
that in 3T3 cells (Figure 2E). Analysis of the level of ERK that was
phosphorylated only at the tyrosine residue and not at the
threonine residue (pYERK), which was assessed using a specific
antibody, yielded interesting results. The intensity of the pYERK
band increased at 15 min after costimulation with EGF+COL, but
then decreased to the original level within 30 min in 3T3 cells.
The change was more marked after costimulation of 3T3-B56c1
cells than after co-stimulation of 3T3 cells (Figure 2E). Similar
results were obtained when the same experiment was performed
using Calu1 cells (Figure 2E). All of these results suggested that
pTpYERK is dephosphorylated (inactivated/inhibited) by PP2A-
B56c1, a serine/threonine phosphatase that dephosphorylates
phospho-threonine in the TEY motif.
Figure 7. The strength and duration of ERK activation is determined by MEK and PP2A-B56c1 activities. (A) The activity of PP2A-B56c1
phosphatase measured by immune complex fluorometric phosphatase assay using 4-methylumbelliferyl phosphate as a substrate. The closed
squares indicate the measured phosphatase activity. Two areas demarcated by dotted lines (‘‘transient phosphorylation’’ and ‘‘IER3’’) were deduced
from the effect of two distinct factors, i.e., the rapid inactivation of phosphatase activity (probably due to phosphorylation of the C subunit of PP2A)
and the later PP2A inactivation reaction by IER3. C subunits of PP2A in the immune complex were detected by western blotting using anti-C subunit
antibodies. Since faint blot at 3 min shows non-specific binding to Sepharose beads, densities of non-immune controls (C) and of 3 min are being
compared. (B) The kinetics of ERK and MEK activities in Calu1 cells were examined by western blotting. The plot was constructed using data from 3 (0
to 15 min) or 9 (0, 15 to 60 min) repeated experiments.
doi:10.1371/journal.pone.0063729.g007
Figure 8. Schematic illustration of proposed mechanisms of ERK-mediated cell migration regulated by PP2A-B56c1. The numbers 1, 2
and 3 indicate the main signalling pathways that regulate ERK activation within the first 60 min following stimulation.
doi:10.1371/journal.pone.0063729.g008
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PP2A-B56c1 Dephosphorylates ERK in Nuclei
Possible colocalization of B56 proteins and pTpYERK within
cells was examined by immunofluorescence. All of the cell lines
analyzed were treated with EGF and placed on collagen for
30 min, followed by immunofluorescence analysis of protein
localization. Using a conventional immunofluorescence micro-
scope, B56c1 in 3T3-B56c1 cells, detected with anti-mouse B56c1
antibodies and fluorescence-labelled secondary antibodies, ap-
peared to be localized in both the nuclei and the perinuclear area.
Since non-specific fluorescence in the perinuclear area can be an
issue in conventional fluorescence microscopy, a confocal laser
scanning microscope was next used to examine fluorescence in
thin tissue slices. In serial 1-mm-thick sections, B56c1 in 3T3-
B56c1 cells and pTpYERK in 3T3 cells were clearly localized in
nuclei, and no fluorescence signal was observed in the perinuclear
region (Figure 3A). pTpYERK immunofluorescence was also
detected in the nuclei of Calu1 cells using a confocal laser scanning
microscope (Figure 3A). The subcellular localization of B56a1,
B56b1, and B56c1 was further examined by immunofluorescence
analysis of permanently B56-transfected Calu1 cells, using anti-
HA antibodies. Both B56a1 and B56b1 were localized in the
perinuclear area (Figure 3B). B56c1 was localized only in nuclei
and was not seen in any other subcellular localization (Figure 3B).
Immunolocalization of B56c1 was also examined in the
presence and the absence of EGF in pCalu1-B56c1 cells on
collagen. Immunofluorescence of B56c1 was not clearly observed
when the cells were not stimulated with EGF, but was detected in
the nuclei at 30 to 60 min after EGF stimulation (Figure 3C).
Quantitatively, western blot analysis in nuclear protein extracted
from Calu1-B56c1 cells using anti-HA antibodies showed increase
in B56c1 protein in nuclei after cells were treated with EGF and
loaded on collagen (Fig. 3D).
HA-B56 proteins were each immunoprecipitated with anti-HA
antibodies from lysates of permanently B56-transfected Call1 cells,
and co-precipitating endogenous pTpYERK was analysed by
western blotting using anti-pTpYERK antibodies. This experi-
ment showed that B56a1 and B56b1 did not bind to pTpYERK,
but that B56c1 did bind to pTpYERK (Figure 4A). B56c1 protein
was found to co-precipitate with pTpYERK (Figure 4A). To
determine the ability of PP2A associated with different B56
subunits to dephosphorylate pTpYERK, in vitro immune com-
plex phosphatase assays were performed. PP2A that co-precipi-
tated with HA-tagged B56 proteins from each pCalu1-B56 cell line
was incubated with pTpYERK-rich cell lysates, i.e., lysates of
Calu1 cells that had been stimulated with EGF for 30 min. The
effect of this incubation on pTpYERK phosphorylation was
analysed by western blotting. This experiment showed that PP2A-
B56c1 dephosphorylated pTpYERK, but that PP2A-B56a1 and
PP2A-B56b1 did not (Figure 4B), although the amounts of the
immunoprecipitated B56s varied somewhat (Figure 4B).
IER3 Induces Cell Migration via Sustained Activation of
ERK
It was suggested that immediate early response protein3, IER3
(formerly known as IEX1) induced sustained activation of ERK
[66] by inhibiting B56-containing PP2A [39]. Indeed, we found,
by using a pulldown assay, that IER3 binds to B56c1 (Figure 4A).
IER3 was not coprecipitated with B56a1 and B56b1 by the
pulldown assay (Figure 4A). If IER3 induces sustained activation of
ERK for cell migration through interaction with PP2A-B56c1, the
IER3 protein should be fully expressed within 30 min after
costimulation with EGF plus COL. It has been reported that the
expression of IER3 mRNA starts within 10 minutes after EGF
stimulation [67], but it is not known exactly how long it takes for
IER3 protein expression to begin. We therefore examined the
kinetics of IER3 protein expression following stimulation with
EGF or EGF+COL. Unglycosylated and glycosylated forms of
IER3 were visualized by western blotting (Figure 5A) and dot blot
analysis was used for quantification. We found that, when the cells
were stimulated with EGF or EGF+COL, IER3 protein was
moderately expressed within 15 min (Figure 5B), suggesting that
the protein expression started within a few minutes of stimulation.
The IER3 protein accumulated more rapidly when the cells were
stimulated with EGF+COL than when they were stimulated with
EGF alone (Figure 5B). These results led us to re-examine the
effect of cycloheximide on EGF-induced migration at an early
time point, and we found that cycloheximide inhibited EGF-
induced cell migration at 1 hour after EGF administration
(Figure 5C).
We next determined the effect of IER3 knockdown on cell
migration. RNAi against IER3 inhibited the migration of Calu1
cells (Figure 6A). The rate of decrease in migration was 20% at 9-
hour migration, which was less than the effect of B56c1
overexpression (Figure 2D), and then the inhibitory efficiency of
mRNA expression was measured by a real time PCR. The
inhibition of the expression of IER3 mRNA was not complete but
38% (Figure 6B). When Calu1 cells or Calu1 cells transfected with
mock d-siRNA were treated with EGF and loaded onto collagen-
coated glass slides, the cells exhibited cytoplasmic processes
(Figure 6C). When Calu1 cells were transfected with IER3 d-
siRNA, generation of these cell processes was inhibited (Figure 6C),
indicating that these cells would have low migratory activity [60].
To quantify the difference in the effect between mock RNAi and
IER3 RNAi, the numbers of cells with cytoplasmic processes were
counted under a fluorescence microscope. There was a significant
difference in the percentages of cells positive for cytoplasmic
processes (Figure 6B). The effects of IER3 knockdown on ERK
phosphorylation were also examined by western blotting using
anti-pTpYERK and anti-pYERK antibodies. IER3 knockdown
led to enhanced dephosphorylation of pTpYERK, resulting in a
change from sustained activation to transient activation of ERK
(Figure 6D). In contrast, IER3 knockdown changed the transient
increase in pYERK to a sustained increase by enhancing
dephosphorylation of pTpYERK at the threonine residue
(Figure 6D).
Kinetics of Activities of B56c1, ERK and MEK Following
EGF/COL Stimulation
Calu1-B56c1 cells were stimulated with EGF/COL, and PP2A-
B56c1 phosphatase activity between 0 and 60 min, especially
during the first 15 min period, was examined using an immune
complex fluorometric assay. Unexpectedly, these data showed that
PP2A-B56c1 activity dramatically decreased within 1 min of
stimulation, to the point where no activity could be detected
(Figure 7A). However, after a few more minutes, PP2A-B56c1
activity started to increase, and then it gradually increased over the
next 15 min, and was maintained at approximately the same level
between 15 min and 60 min (Figure 7A). The recovered activity
was lower than the initial activity. The kinetics of phosphatase
activity over the entire 60 min after stimulation suggested the
existence of two different phases. The earlier phase involves a
robust inactivation, and the later phase shows a sustained
moderate activation. We next analyzed the presence of the
catalytic C subunit of PP2A in the same HA-precipitated immune
complexes by western blotting using anti-Csubunit antibodies. The
C subunit that was initially bound to B56c1 was not detected in
precipitates between 1 to 5 min after treatment but was detected at
subsequent time points and its levels were maintained at an
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approximately similar level between 15 min and 60 min of
stimulation. The time course of the association of the C subunit
of PP2A was coincident with the kinetics of PP2A-B56c1
phosphatase activities (Fig. 7A).
Sustained inactivation of PP2A-B56c1 phosphatase activity
should correspond with sustained phosphorylation of ERK. We
therefore reassessed the kinetics of ERK phosphorylation in the
later phase following EGF/COL stimulation. The intensities of the
bands of pTpYERK previously obtained by western blotting were
plotted (Figure 7B). The plot of the kinetics of pTpYERK
phosphorylation was the reciprocal of that of PP2A-B56c1 activity
(Figure 7A, B). We also examined the kinetics of pTpYERK
phosphorylation in the early phase following EGF/COL treat-
ment (Figure 7B). The highest peak of pTpYERK phosphorylation
was at 5 min, which was 4 min after the initiation of PP2A-B56c1
inactivation. To determine the significance of the inactivation of
PP2A-B56c1 phosphatase activity, we next analysed the kinetics of
MEK phosphorylation. It is well established that MEK is a dual
kinase that is required for ERK activation. The kinetics of MEK
activation was determined by western blotting of the active form of
MEK, which is MEK that is phosphorylated at Ser217/221
(pMEK), using the same cell lysates as those used for analysis of
the early kinetics of pTpYERK. Similar to pTpYERK, the level of
pMEK also reached a maximum at 5 min after the start of
stimulation. The level of pMEK decreased more rapidly than the
level of pTpYERK (Figure 7B). The combined data suggest that
inactivation of PP2A-B56c1 prior to the initiation of MEK and
ERK phosphorylation could be involved in transmission of the
signal from MEK to ERK.
The subsequent changes in PP2A-B56c1 activity over time
presumably affect the phosphorylation of ERK as follows. After
activated MEK has fully phosphorylated ERK at 5 min and
pMEK has decreased, ERK phosphorylation would still be
increasing as a consequence of overall MEK activity, even if the
level was low, unless PP2A-B56c1 was able to access pTpYERK.
The activity of PP2A-B56c1 at 15 min after stimulation, which
had recovered to half the original level of activity at time 0, would
decrease the MEK-induced phosphorylation of ERK at 15 min.
Indeed MEK phosphorylation had decreased to half the peak
value by 15 min. Therefore, the level of ERK phosphorylation
would be maintained at the same level due to the balance of the
opposing actions of MEK1 and PP2A-B56c1.
Discussion
McCright et al. [68] reported that B56a1 and B56b1 are
localized in cytoplasm, and that B56c1 is concentrated in nuclei.
Other studies have reported that B56c1 is localized in focal
contacts together with paxillin [46] and also in the Golgi complex
[63]. These conflicting data regarding the localization of B56c1
may have led to misinterpretation of its functions. However, we
confirmed here that B56c1 is localized in nuclei by means of a
confocal laser scanning microscopic study using the same anti-
mouse B56c1 antibody and the same animal species as those used
by Ito et al. [46,63]. The reported difference in B56c1 localization
between their work and ours could be due to the presence or
absence of stimulation. Furthermore, B56c1 inhibited migration,
formed a complex with pTpYERK, probably together with the A
and C subunits of PP2A, and dephosphorylated pTpYERK in cell
lysates. Among the results obtained in the present study, we could
not detect association of B56c1 and pTpYERK by immunoflu-
orescence but by pulldown assay. The enzyme-substrate reaction
should be prompt as the immunofluorescence could not detect the
association. However, the reaction should not have been
completed so promptly, and the unreacted substrates could have
been observed by the pulldown assay. Thus, B56c1 functions to
regulate nuclear ERK activation through dephosphorylation at the
TEY motif.
The combined results of the present study showed that there is
an interaction between IER3 and PP2A-B56c1, which results in
IER3-mediated inhibition of the dephosphorylation of pTpYERK,
thereby leading to sustained ERK activation in the nucleus and
cell migration. Our findings reveal two important aspects of IER3
regulatory function towards B56c1. First, we showed that IER3
expression started within a few minutes after stimulation. Second,
we showed that the kinetics both of sustained ERK activation and
augmented IER synthesis were caused by costimulation of EGF
and collagen adhesion. Sustained ERK activation is likely to be
caused indirectly via the effect of augmented IER3 synthesis on
PP2A-B56c1 activity, since an inhibitory effect of IER3 on PP2A-
B56c1 activity via release of the C subunit has already been
reported by Letourneux et al. [39]. The expression of IER3 in
costimulated cells was higher than that in the cells stimulated with
EGF alone, possibly due to the greater ERK activation. The
expression level is high enough to prevent ERK dephosphoryla-
tion in conjunction with decreased but still substantial MEK
activity, leading to sustained activation of ERK in a positive
feedback manner.
The kinetics of PP2A-B56c1 activity suggested that the observed
inactivation of PP2A-B56c1 phosphatase was caused by two
different mechanisms. The later phase of phosphatase inactivation
could be due to newly synthesized IER3 (Figure 7A right upper
triangle demarcated by dotted lines), which induces sustained
activation of ERK leading to cell migration. On the other hand,
PP2A-B56c1 activity was lost rapidly in the earlier phase.
Considering that there is a background level of phosphatase
activity of PP2A-B56c1 at 0 min in Calu1 carcinoma cells, one
possibility is that the extinction of PP2A-B56c1 activity in the early
phase might be important to achieve stable signalling for induction
of ERK phosphorylation. Unless constitutively active PP2A-B56c1
was inactivated, as found in the present study, ERK phosphor-
ylation would be influenced by PP2A-B56c1 activity. This
situation would result in a decrease in the level of pTpYERK
and also in an unstable signal dependent upon background
phosphatase activities. Thus, the transient extinction of PP2A may
play a passive but extremely important role in ensuring the fidelity
of the strength of ERK activation. The rapid inhibition of PP2A-
B56c1 activity might be the same event as previously reported
[69,70]; in that work, Src transiently inactivated the phosphatase
activity of PP2A by phosphorylation of the C subunit at Tyr307,
leading to dissociation of the C subunit from PP2A heterotrimer
[70]. However, it was also noted that the peak of inactivation of
PP2A was at 15 min after stimulation [70]. If that were the case,
the significance of the phenomenon would be totally different from
what we suggest here, as they claimed that the transient
deactivation of PP2A might enhance transmission of the cellular
signal [69]. However, the time lag in their case might have been
due to their experimental procedure. If the reported inactivation
signal from Src was the same signal as the immediate inactivation
of PP2A in the present study, it could have originated both from
growth factor receptor and integrin, since it has been reported that
a growth factor receptor caused PP2A deactivation through Src
[69] and Src is involved in integrin-generated signals [71]. Thus,
the immediate robust inactivation of PP2A-B56c1 could be due to
transient phosphorylation/inactivation of PP2A (Figure 7A left
area demarcated by dotted lines and a solid line), and the
synergistic Src-PP2A-ERK signal should be synchronized to the
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synergistic MEK-ERK signal from growth factor and integrin-
mediated anchorage [16].
The PP2A B56c gene encodes four differentially spliced forms,
PP2A-B56c1, c2, c3 and c4. Amino acids of the spliced variants
are identical until exon 12, and B56c2, c3, and c4 have an
additional exon or exons [72,73]. In regard to a specific binding
domain, they all have the same amino acids from 391 to 402,
which constitute a domain required for interaction with p53 [49].
Indeed, PP2A-B56c1, c2 nd c3 have been reported to dephos-
phorylate p53 protein at Ser15 [48,49,74]. Similarly, all the
cvariants could be plausible to bind to ERK as the present study
showed that B56c1 bound to and phosphorylated ERK. Presum-
ably, B56c1 have a specific binding site to ERK, which has not
been determined yet. In addition, other isoforms of B subunit
might phosphorylate ERK in the cytoplasm as PP2AB56c1 did in
the nucleus, since phosphorylated ERK localizes not only in the
nucleus but anywhere in the cytoplasm [4].
Conclusions
Our results indicate that the strength and duration of ERK
activity are regulated by a combination of MEK and PP2A-B56c1
activities. We propose that the machinery of the spatio-temporal
regulation of ERK is as illustrated in Figure 8. First, MEK
activates ERK (Figure 8-1). The ERK activity transmitted by
MEK is initially unaffected by B56c1-PP2A due to its prompt
extinction (Figure 8-2), but subsequently the balance of MEK and
B56c1-PP2A activities determines the strength of ERK activation.
A positive feedback loop involving IER3-B56c1-phosphorylated
ERK (Figure 8-3) determines the duration of ERK activation.
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